Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Monopar Therapeutics Inc.NASDAQ: MNPR
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets falls 52.1% from a year ago
Other current assets stood at $250.9K at the end of Q1 FY2026, down 52.1% from a year earlier and up 293.6% from the prior quarter. Over 3 fiscal years it compounded at +11.5% a year.
Context
- Other current assets amounted to 0.2% of total assets at the end of Q1 FY2026, down 0.8 pp from a year earlier.
- Other current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether other current assets keeps falling in the next quarterly balance sheet after a -52.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 63.75K USD
- Year-over-year change
- -19.2%
- 4-year CAGR
- -26.4%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 63.75K | -19.2% |
| FY2024 | 2024-12-31 | 78.87K | +18.7% |
| FY2023 | 2023-12-31 | 66.43K | +44.5% |
| FY2022 | 2022-12-31 | 45.98K | -78.9% |
| FY2021 | 2021-12-31 | 217.75K | — |
Other Current Assets vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so other current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -52.1% is the 5th highest of 9, against a peer median of -43.2%.
- Other current assets amounts to 0.2% of total assets for MNPR, versus a peer median of 1.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $18.74M USD | +12.0% | — | 2.9% | |
| Sep 2026 | $16.21M USD | +122.6% | — | 3.2% | |
| Mar 2026 | $9.94M USD | +38.4% | +288.8% | 3.4% | |
| Mar 2026 | $8.37M USD | +4.9% | -4.9% | 3.8% | |
| Mar 2026 | $5.24M USD | — | +5.8% | 2.9% | |
| Mar 2026 | $1M USD | -91.3% | -51.9% | 0.5% | |
| Mar 2026 | $250.9K USD | -52.1% | +11.5% | 0.2% | |
| Jun 2026 | $0 USD | -100.0% | -0.7% | 0.0% | |
| Sep 2026 | $0 USD | -100.0% | — | 0.0% | |
| Jun 2026 | $0 USD | -100.0% | +51.7% | 0.0% | |
| Dec 2025 | -€4.28K EUR | — | — | 0.0% | |
| Peer median (excluding MNPR) | — | -43.2% | +2.5% | 1.7% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.